Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 122


Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors.

Mitra AK, Mukherjee UK, Harding T, Jang JS, Stessman H, Li Y, Abyzov A, Jen J, Kumar S, Rajkumar V, Van Ness B.

Leukemia. 2015 Dec 29. doi: 10.1038/leu.2015.361. [Epub ahead of print]


Returning a Research Participant's Genomic Results to Relatives: Perspectives from Managers of Two Distinct Research Biobanks.

Petersen GM, Van Ness B.

J Law Med Ethics. 2015 Fall;43(3):523-8. doi: 10.1111/jlme.12294.


Returning a Research Participant's Genomic Results to Relatives: Analysis and Recommendations.

Wolf SM, Branum R, Koenig BA, Petersen GM, Berry SA, Beskow LM, Daly MB, Fernandez CV, Green RC, LeRoy BS, Lindor NM, O'Rourke PP, Breitkopf CR, Rothstein MA, Van Ness B, Wilfond BS.

J Law Med Ethics. 2015 Fall;43(3):440-63. doi: 10.1111/jlme.12288.


Risk of multiple myeloma in a case-spouse study.

Andreotti G, Katz M, Hoering A, Van Ness B, Crowley J, Morgan G, Hoover RN, Baris D, Durie B.

Leuk Lymphoma. 2016 Jun;57(6):1450-9. doi: 10.3109/10428194.2015.1094693. Epub 2015 Nov 16.


Applications and limitations in translating genomics to clinical practice.

Van Ness B.

Transl Res. 2016 Feb;168:1-5. doi: 10.1016/j.trsl.2015.04.012. Epub 2015 May 4. Review.


Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma.

Fall DJ, Stessman H, Patel SS, Sachs Z, Van Ness BG, Baughn LB, Linden MA.

J Cancer. 2014 Sep 21;5(9):720-7. doi: 10.7150/jca.9864. eCollection 2014. Review.


High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG.

Leukemia. 2014 Nov;28(11):2263-7. doi: 10.1038/leu.2014.214. Epub 2014 Jul 9. No abstract available.


Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma.

Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB.

PLoS One. 2013 Oct 29;8(10):e77608. doi: 10.1371/journal.pone.0077608. eCollection 2013.


Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency.

Stessman HA, Mansoor A, Linden MA, Van Ness B, Baughn LB.

Leuk Lymphoma. 2014 Jan;55(1):220-2. doi: 10.3109/10428194.2013.797575. Epub 2013 Jun 4. No abstract available.


Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.

Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B.

Leukemia. 2013 Oct;27(10):2075-7. doi: 10.1038/leu.2013.148. Epub 2013 May 14. No abstract available.


Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG.

Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.


High-order SNP combinations associated with complex diseases: efficient discovery, statistical power and functional interactions.

Fang G, Haznadar M, Wang W, Yu H, Steinbach M, Church TR, Oetting WS, Van Ness B, Kumar V.

PLoS One. 2012;7(4):e33531. doi: 10.1371/journal.pone.0033531. Epub 2012 Apr 19.


Managing incidental findings and research results in genomic research involving biobanks and archived data sets.

Wolf SM, Crock BN, Van Ness B, Lawrenz F, Kahn JP, Beskow LM, Cho MK, Christman MF, Green RC, Hall R, Illes J, Keane M, Knoppers BM, Koenig BA, Kohane IS, Leroy B, Maschke KJ, McGeveran W, Ossorio P, Parker LS, Petersen GM, Richardson HS, Scott JA, Terry SF, Wilfond BS, Wolf WA.

Genet Med. 2012 Apr;14(4):361-84. doi: 10.1038/gim.2012.23.


Return of individual research results and incidental findings in the clinical trials cooperative group setting.

Ferriere M, Van Ness B.

Genet Med. 2012 Apr;14(4):411-6. doi: 10.1038/gim.2012.14. Epub 2012 Mar 1.


Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.

Linden MA, Kirchhof N, Carlson CS, Van Ness BG.

Exp Hematol. 2012 Mar;40(3):216-27. doi: 10.1016/j.exphem.2011.11.006. Epub 2011 Nov 23.


Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.

Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S.

Clin Cancer Res. 2011 Dec 1;17(23):7313-23. doi: 10.1158/1078-0432.CCR-11-0636. Epub 2011 Sep 8.


Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.

Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BG, Van Ness B, Child JA, Sonneveld P, Morgan GJ.

J Clin Oncol. 2011 Mar 1;29(7):797-804. doi: 10.1200/JCO.2010.28.0792. Epub 2011 Jan 18.


Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis.

Minarik J, Scudla V, Ordeltova M, Pika T, Bacovsky J, Steinbach M, Kumar V, Van Ness B.

Leuk Res. 2011 Jan;35(1):44-8. doi: 10.1016/j.leukres.2010.04.015. Epub 2010 May 21.


Interaction of CYP1B1, cigarette-smoke carcinogen metabolism, and lung cancer risk.

Church TR, Haznadar M, Geisser MS, Anderson KE, Caporaso NE, Le C, Abdullah SB, Hecht SS, Oken MM, Van Ness B.

Int J Mol Epidemiol Genet. 2010 Aug 5;1(4):295-309.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk